Showing 1 - 10 of 567
Governments and firms often use committees of experts to help them make complexdecisions, but conflicts of interest could bias experts' recommendations. We focus on whetherfinancial ties to drug companies bias FDA drug advisory committee (AC) members' voting ondrug approval recommendations. We...
Persistent link: https://www.econbiz.de/10012934325
This article examines the implications of U.S. federal and international regulatory mandates in the construction and circulation of racial categories in biomedical research and drug development. It will focus on the interface between two regulatory mandates in particular: the International...
Persistent link: https://www.econbiz.de/10014053161
In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...
Persistent link: https://www.econbiz.de/10014060120
This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process. Lack of competition in the drug approval process has led to exceedingly high drug development costs....
Persistent link: https://www.econbiz.de/10004995401
We evaluate the impact of a price cap regulation implemented in the Colombian pharmaceutical market between 2011 and 2014. To do so, we take advantage of a unique data set where we observe three sources of variation: i) differences across eighteen groups in the Anatomical Therapeutic Chemical...
Persistent link: https://www.econbiz.de/10013238087
Coronavirus Disease 2019 (COVID-19) vaccinations play a main role in the immunization campaign of nations but countries, after a certain share of people vaccinated have to cope with vaccine hesitancy and resistance in population. The goal of this study here is the detection of the max share of...
Persistent link: https://www.econbiz.de/10013312616
This article analyzes the shifts of power relation and influence between pharmaceutical industry (producers), pharmacies, and social health insurers (SHI) in Germany based on drug prices. Since the health care reform of 2004, these interest groups have negotiated fees and discounts among each...
Persistent link: https://www.econbiz.de/10010529890
I evaluate how the probability of substitution of a prescribed drug in a pharmacy depends on the pharmacists' profits and patients' out of pocket costs. I use Finnish population-wide data covering all prescriptions of three popular antidepressants. I find that one euro increase in the total...
Persistent link: https://www.econbiz.de/10011954334
Very few industries are as profoundly influenced by regulation as the pharmaceutical industry. All aspects of the life-cycle of new drugs are regulated, from patent application, to marketing approval, commercial exploitation, patent expiration and competition with generics. The nature of demand...
Persistent link: https://www.econbiz.de/10012980141
The established role of pharmaceutical products in the current health care landscape combined with increasing reports of serious and often fatal toxicity associated with these products have led to growing calls for reform of drug regulation. The growing public-private partnerships in research...
Persistent link: https://www.econbiz.de/10012752017